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Abstract
Background Sedative hypnotics form an important part of managing
insomnia and are recommended for short-term use. It is standard
practice for clinicians to inform the patient to use medications only
‘when required’, but the use of these medications is often chronic. Lit-
tle is known about the impact of standard labelling/instructions on
promoting appropriate medication use for managing insomnia.
Objective To explore patient medication-taking beliefs, experiences
and behavioural practices relating to the use of pharmacological/
complementary sleep aids for insomnia.
Setting and Participants Specialist sleep/psychology clinics and the
general community in Sydney, Australia.
Method Semi-structured interviews were conducted with 51 people
with insomnia using a schedule of questions to gauge their experi-
ences, beliefs and current practices relating to insomnia medication
use. Interviews were audio-recorded, transcribed verbatim and
subjected to Framework Analysis to identify emergent themes.
Results Participants held distinctive views about the safety and
efficacy of complementary and pharmacological agents but do not
intuitively turn to medications to resolve their sleep complaint.
Medication use was affirmed through tangible medication-taking
cues due to the ambivalence in current instructions and labelling.
Practices such as dosage modiﬁcation, medication substitution and
delaying medication use might be important drivers for psychologi-
cal dependence.
Conclusion Current labelling and instructions do not necessarily
promote the quality use of sedative hypnotics due to the variability
in patient interpretations. Clarifying the timing, quantity and fre-
quency of medication administration as well as insomnia symptom
recognition would play a signiﬁcant role in optimizing the role of
pharmacotherapy in the management of insomnia.
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Introduction
Insomnia is the most prevalent sleep com-
plaint in clinical practice. Psycho-behavioural
approaches are universally advocated as ﬁrst-
line treatment across multidisciplinary best prac-
tice guidelines. Pharmacological treatment is
eﬀective, but recommended for short-term relief
only and should ideally be accompanied by
behavioural treatments.1 However, sedative
hypnotics (e.g. benzodiazepines, z-drugs and
sedating antihistamines) continue to be widely
used for extended periods of time in the routine
management of insomnia.2 Acutely, sedative
hypnotics impair psychomotor vigilance which,
depending on the time of administration, can
extend into the next day and pose safety con-
cerns around an individual’s ﬁtness to drive.3–5
Long-term, extended sedative hypnotics use has
been associated with cognitive impairment, falls,
increased mortality, potential for dependence
and abuse and the possible risk of developing
dementia.6,7 Although these eﬀects are more
pronounced in the elderly, this patient popula-
tion remains the largest consumers of sedative
hypnotics.8 Collectively, the adverse outcomes
associated with sedative hypnotics contributes
substantially, both directly and indirectly, to the
health-care expenditure.9 As a result, limiting
patient exposure to pharmacological sleep aids
has been an important agenda across diﬀerent
clinical contexts.10–12 Strategies include prescrib-
ing hypnotics on a ‘when required’ (PRN) basis,
avoiding concomitant alcohol use, medication-
tapering programmes11,13 and the development
of low-dose (i.e. 3.5 mg) ‘middle of the night’
sublingual formulations of zolpidem.14 Table 1
outlines how the respective strategies intend to
promote the quality use of sedative hypnotics in
clinical practice.
Whilst adverse consequences associated with
the various hypnotics might stem from their
inherent pharmacological properties, potential
interactions arising from concomitant sleep aids
use (e.g. OTC/CAMs), the extent to which the
patient accurately interprets the labelling,
instructions and precautionary measures also
have important therapeutic, safety and health
economic implications.3,15 From the perspective
of patient safety, risk communication (i.e. ﬁtness
to drive) is becoming an increasingly important
area of focus in the provision of psychotropic
medications including sedative hypnotics which
are routinely used for the management of insom-
nia.16 Interventions include the use of dispensing
software support tools17 and incorporating pic-
tograms on ancillary warnings to enhance
decision making around sedation risk.16 How-
ever, within the current scope of pharmacy
practice in Australia, this message is only
reinforced through counselling and basic
labelling/ancillary warnings relating to concomi-
tant alcohol consumption and sedation risk.
Furthermore, despite the widespread use of com-
plementary sleep aids, its connection between
the perceived safety and prolonged use of phar-
macological agents is unknown.18
As required ‘PRN’ self-administration of
medication has a long-standing history in medi-
cal practice and is widely applied in disciplines
ranging from pain management (e.g. opioids),19
Table 1 Clinical interventions for promoting the quality use
of sedative hypnotics in clinical practice
Strategy Purpose
PRN
prescribing
Promote intermittent use of medication
to limit patient exposure to sedative
hypnotics to only times of need
Avoid concomitant
alcohol use
Prevent additive sedation when both
sedative hypnotics and alcohol are
consumed concurrently. Important
safety implications for engaging in
tasks requiring psychomotor vigilance
the next morning (e.g. driving)
Medication-
tapering
programmes
Limit exposure of these medications and
curtail potential consequences (e.g.
dependence, abuse, cognitive decline)
associated with long-term use
Low-dose
sublingual
‘middle of the
night’
zolpidem
formulation
Rapid onset of action and prevents
residual sedation associated with
taking standard doses of zolpidem (i.e.
conventional tablet: 5–10 mg;
controlled release: 6.25–12.5 mg)
when experiencing sleep maintenance
insomnia. Important safety implications
for engaging in tasks requiring
psychomotor vigilance the next
morning (e.g. driving)
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gout management (e.g. colchicine in acute
attacks)20 to insomnia (e.g. sedative hypnotics).1
The premise of doing so is to prevent the overuse
of medications given the inevitable ﬂuctuations
in symptomology throughout the course of the
respective disease states.21 However, the impact
of this strategy on promoting the safe use of
sedative hypnotics is unknown. In a study inves-
tigating patients’ health literacy, ‘take one pill
by mouth every 12 h with a meal’ was only
correctly interpreted by 53% (n = 359) of partic-
ipants.22 It is expected that less explicit
instructions such as ‘use when required’ which
rely on patients’ self-assessment could result in
even higher rates of misinterpretation.15,22,23
Promoting intermittent sedative hypnotic use in
the management of insomnia is also complicated
by a combination of health system and psy-
chosocial factors including the limited access to
cognitive behavioural therapy for insomnia
(CBT-I), the patients’ unique set of treatment
beliefs (i.e. perceived medication need/usefulness
for addressing insomnia) and what is communi-
cated to the patient by their health-care
provider.24–26 These factors are likely to dictate
whether or not the patient chooses to take, how
they take their sleep medications and whether or
not these medications are being used safely.27
Therefore, the primary aim of this study was to
explore patient beliefs and behavioural practices
and their perception of sedation risk relating
to the use of pharmacological and non-
pharmacological sleep aids for insomnia.
Methods
Recruitment
To capture diverse treatment experiences that
are representative of the heterogeneous insomnia
patient population, we invited clinicians from
primary care practices (e.g. community phar-
macy and general practice) and specialist clinics
(i.e. Woolcock Institute of Medical Research
Sleep Clinic and Headspace) to be involved in
the study. Their primary role was to inform suit-
able participants about the nature of the study
and the contact details of the researchers. In
addition, advertisement ﬂyers were displayed
around these settings and the university commu-
nity for participants to directly contact the
researchers. Inclusion criteria for this study
required participants to be ≥18 years of age,
diagnosed with insomnia and/or referred to the
study by their clinician or have self-reported
insomnia symptoms that meet the diagnostic cri-
teria of the International Classiﬁcation of Sleep
Disorders 2nd Edition (ICSD-2).28 People with
insomnia were given a $50 voucher for their par-
ticipation in the study. Study protocols were
approved by the University of Sydney Human
Research Ethics Committee (HREC: 2013/679).
Informed consent and conﬁdentiality agree-
ments were sought from each participant prior
to the interview.
Data collection
Individual semi-structured interviews were con-
ducted by the ﬁrst author (JC) either face-to-
face or via telephone. The interview was guided
by a schedule of questions (Appendix S1)
exploring patients’ perceptions towards medica-
tion use for insomnia, current medication-taking
routines and their understanding of standard
labelling and instructions for pharmacological
and/or complementary agents used to induce
sleep. Interviews were digitally recorded then
transcribed verbatim for analysis. Participants
also completed a pre-interview questionnaire
which collected demographic information, a
brief insomnia history, the Insomnia Severity Index
(ISI)29 and Beliefs about Medicines Questionnaire
General* (BMQ-Harm, BMQ-Overuse).30,31 Data
collection continued until thematic saturation was
independently achieved for the clinic (n = 22) and
community (n = 29) population (i.e. Subsequent
interviews did not provide additional thematic
categories pertaining to the experiences of medi-
cation use of the respective patient groups).
*The BMQ general is made up of two components a General
Harm scale (ﬁve items, total scores range from 5 to 25) and a
General Overuse scale (three items, total scores range from 3
to 15) assessing beliefs about pharmaceuticals as a class of
treatment.
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Analysis
Interviews were audio-recorded, transcribed
verbatim and de-identiﬁed. Transcripts were
analysed using Framework Analysis (FA) as
described by Ritchie and Spencer and was car-
ried out using QSR NVivo 10 software©.32 FA
allows for the incorporation of multiple patient
perspectives on the same phenomenon (i.e. medi-
cation experiences and practices). Analysis
typically involves ﬁve key stages consisting of
familiarization, identiﬁcation of a thematic
framework, indexing, chartering and ﬁnally
mapping and interpretation. During familiariza-
tion, individual transcripts and ﬁeld notes were
read iteratively by JC and BS to understand
some of the concepts and issues raised by partici-
pants. Emerging concepts were merged with the
a priori concepts set out by the schedule of ques-
tions (see Appendix S1) and formed the basis
of our preliminary thematic framework. New
themes arising from subsequent interviews and
analysis were discussed at research meetings and
were iteratively incorporated into the developing
thematic framework. The ﬁnal thematic frame-
work was applied systematically across the data
set to index units of text corresponding to a
particular theme, and earlier cases were also
subject to re-analysis. The indexed data were
further re-organized into thematic matrices con-
taining thematic categories that were related to
each other. In the ﬁnal stage, mapping and
interpretation, where cross-case and within-case
associations were explored and discussed with
the research team to conceptualize thematic cat-
egories that ultimately formed the set emergent
themes presented.
Results
Sample characteristics
Fifty-one semi-structured interviews were con-
ducted between August 2013 and May 2014
either through telephone (n = 36) or face-to-face
(n = 15). The duration of interviews ranged
from 39 to 139 min (median = 68 min). The 51
patients ranged between 19 and 69 years of age
with a mean duration of insomnia of 10.2 and
11.2 years for the clinic (n = 22) and community
population (n = 29), respectively. However, very
little diﬀerence was observed across measures
between the clinic and community patient
sample. Table 2 summarizes participant demo-
graphic information. Patients reported using a
broad range of sleep-promoting agents including
complementary, over-the-counter (OTC) and
prescription items (Table 2). Complemen-
tary sleep aids included the use of proprietary
formulations, herbal concoctions, teas and aro-
matherapy. Three participants (P8, P16 and
P37) reported not having taken any sleep aids
but having just explored (‘looked into’) diﬀer-
ent options.
Synthesis of the qualitative data revealed three
key themes: Treatment Beliefs, Taking Medica-
tion and Following Instructions. Where relevant
participant extracts have been included to illus-
trate the organization of the emergent themes.
Each participant is assigned a code with the
letter ‘P’ followed by a number to indicate inter-
view order and then either CL or CM to denote
whether the participant was from a specialist
clinic or community setting, respectively, fol-
lowed by their gender and age.
Theme 1: Treatment beliefs
The safety of medicines
People with insomnia across the two patient
populations shared similar experiences and
thoughts about the diﬀerent sleep aids
currently available. Irrespective of prior medi-
cation use, it was evident that participants
had attached a diﬀerent meaning and emotion
to the diﬀerent types of sleep aids currently
available on the market. An important consid-
eration among participants revolved around
whether they were taking something that was
‘natural’ or a ‘chemical’. Despite knowing
pharmaceuticals were more eﬀective for induc-
ing sleep people with insomnia disliked taking
sleep medication and tended to favour ‘natu-
ral’ complementary products with the view
that it is gentler on the body and has
less potential to produce adverse eﬀects and
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felt less concerned about taking them.
Interestingly, prescription melatonin was also
considered ‘natural’ and therefore ‘safe’.
I’ll take something that isn’t as eﬀective so it
doesn’t have any negative consequences . . . I
would generally lean towards the more natural
solutions I guess. (P3_CM, Male, Age: 22)
Yeah ‘cause I feel like it’s . . . with the herbal sure
they’re less intense but the ﬂip side is you’re less
likely to get the bad side eﬀects. (P9_CL, Female,
Age: 22)
I felt it’s a more natural remedy than the Temaze-
pam. So I think I was less stressed about taking
it. . . I was sort of bit more relaxed about taking
the Melatonin . . . (P22_CL, Female, Age: 36)
When respondents were probed about the
diﬀerences between OTC and prescription
pharmaceuticals for managing their insomnia,
it was generally agreed that prescription medi-
cations were more potent and more eﬀective
for promoting sleep. However, views towards
the safety of the two were divided around
respondents’ personal feelings towards medical
supervision and the perceived strength of
medication despite clear assignment of medica-
tion categories.† Some participants rationalized
that OTC sleep aids (e.g. doxylamine) was
safer because they were readily accessible with-
out prescription and therefore less potent and
had a smaller potential for serious adverse out-
comes compared to prescription sleep aids,
whereas other participants believed prescrip-
tion items were viewed to be safer on the
premise that a doctor was medically supervis-
ing its use after careful history taking which
may not be as extensive at the pharmacy dur-
ing the provision of OTC sleep aids.
. . .the GP would prescribe it probably after a
prolong conversation about, knowing what’s
going on with someone, they would prescribe
what’s required as opposed to just walking into a
pharmacy and someone who may not fully under-
stand in full what’s going on and prescribes
medication that could cause problems. (P48_CL,
Male, Age: 36)
I don’t know, because it’s over the counter thing
and I think it might be safer than the prescription,
because prescription is probably stronger.
(P51_CM, Female, Age: 56)
Function of the ‘sleeping pill’
People with insomnia saw the role of the phar-
macological ‘sleeping pill’ purely as a means for
resetting and regulating their sleep cycle with the
expectation to cease medication once some sleep
regularity had been restored. Interestingly,
both treatment na€ıve (participant 8) and long-
standing users of sleep aids (participant 17) did
not believe that pharmacological intervention
would be suitable as a long-term treatment solu-
tion as it does not address any of the underlying
issues of insomnia. The perceived lack of a better
Table 2 Participant characteristics
Variable
Community (n = 29)
mean  SD
Clinic (n = 22)
mean  SD
Male 9 6
Female 20 16
Age (years) 43.9  13.4 42.3  14.6
Mean duration of
insomnia (years)
11.2  10.6 10.2  10.3
Mean ISI score 14.1  5.0 12.3  5.0
Mean BMQ (Harm)
score
10.55  2.5 9.2  2.0
Mean BMQ (Overuse)
score
11.8  2.7 11.3  3.3
Usage of sleep aids
Nil 3 0
OTC only 2 1
CAM only 3 2
Rx only 1 1
OTC + CAM 5 2
Rx + CAM 9 4
OTC +CAM + Rx 6 12
BMQ, Beliefs about Medicines Questionnaire; CAM, Complementary
and Alternative Medicine; ISI, Insomnia Severity Index; OTC, Over-the-
counter medication; Rx, Prescription medication.
†In Australia, human medication categories fall under a
wider classiﬁcation system known as: ‘The Poisons Standard’
which includes industrial chemicals (e.g. pesticides) and vet-
erinary chemicals. Within such a scheme, pharmaceuticals
are designated as an OTC (i.e. Schedule 2 and Schedule 3) or
a Prescription item (i.e. Schedule 4 or Schedule 8). This sys-
tem is based on the premise of balancing access to medicines
and self-management of health conditions while protecting
consumers from harm, particularly vulnerable consumer
groups such as children.
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alternative for managing insomnia had been the
main reason for chronic medication use.
I think it (sleeping pill) will help to make my sleep
cycle more regular and let me go to sleep at you
know whatever time um. . . yeah I think it’d just
make it more regular. That’s the role I’d want it to
have. (P8_CM, Female, Age: 27)
I think for short term or intermittent use, they’re
ﬁne but long term no way. It’s not good for long
term because it’s really addictive. (P12_CL,
Female, Age: 29)
I take sleeping tablets, which I try not to-, I am
sort of trying to ﬁgure out the way to get oﬀ them,
but pretty much obviously my body is addicted to
them now, so I lost my natural ability to sleep.
(P17_CM, Female, Age: 42)
On the other hand, complementary sleep aids
(e.g. valerian and non-prescription melatonin)
served a number of roles for diﬀerent people and
reﬂect the heterogeneity of this patient popula-
tion. People with insomnia elected to use these
remedies prior to engaging with pharmacologi-
cal medication. Even for those who regularly use
pharmacological sleep aids, many still continue
to use these remedies as a buﬀer to maintain a
baseline level of sleep, to give the body a break
from medication or were used as part of the
troubleshooting process prior to taking pharma-
cological sleep aids.
Yeah, the Valerian. Yeah, I still take that actually,
I still have one every night, which I-, and I have
chamomile tea too. So, they are both very natural
things. (P11_CL, Female, Age: 61)
‘Less is better’: attitudes towards
pharmacological agents
Sleep was perceived as natural biological process
and medication use violates the beliefs held by
individuals and their contextual surroundings
leading to their intrinsic dislike of taking medi-
cations for insomnia. Concerns stemmed from
the fear of losing ‘natural sleep’, becoming
addicted to medication and potentially harming
the body with chemicals. People referred to ‘nat-
ural sleep’ in terms their perceived quality of
sleep as well as the body’s innate ability and
need for sleep. Using medications to artiﬁcially
induce sleep appears to be incongruent with the
participants’ beliefs about the naturalness of
sleep as a biological process and was further
reaffirmed by their next-morning perceptions of
sleep quality. There was also fear that the body’s
natural sleep drive would diminish with continu-
ous sleep medication use.
. . .even though I was just taking Temazepam just
to get to sleep- but I was never happy about having
to do so. (P22_CL, Female, Age: 36)
To be honest, I don’t like the idea of the actual
sleeping tablet – the reason being is because it sort
of forces you to sleep as opposed to I guess
um. . .making your mind relaxed and fall asleep
naturally. (P36_CM, Male, Age: 21)
For many users of pharmacological sleep aids,
taking as little as possible became a priority
rather than following prescribers’ instructions or
using symptoms to dictate their medication use
and may stem from the aforementioned social
expectations and sleep beliefs. Even when medi-
cation is taken, people with insomnia were often
reluctant to take the full-prescribed dose partly
because of the potential consequence and partly
to prevent medication losing its eﬀect for when
they really want to sleep. Respondents typically
described taking half or a quarter of a tablet to
‘wait and see’ how the body responds. The
remaining portions of medication were only
taken if the initial dose failed to induce sleep and
resulted in multiple subtherapeutic doses over
the course of the night. However, similar beha-
viours were not reported in the use of
complementary sleep aids.
I think probably then I was taking half as well. So
as I said, less is better. But. . . yeah I think. . . do
you know what I mean by that? I prefer to not
take anything so I take as little as I possibly can.
(P14_CL, Female, Age: 31)
I don’t even know if I’d be happy to take something
permanently to put me to sleep because I still
believe, you know, sleep is a natural sort of thing
that should happen and I know that I was always
able to do that on my own without any drugs, so I
would tend not to want to take a prescription tablet
for sleeping, yeah. (P42_CM, Female, Age: 46)
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Theme 2: Taking medication
The meaning of ‘need’
When discussing how participants interpreted the
standard instruction of ‘when required’ (PRN),
many noted that the instruction is vague and that
diﬀerent people have diﬀerent thresholds for
‘needing’ medication. While participants had been
given the autonomy to decide when to take medi-
cation for their insomnia, they were also quite
tentative when it came to exercising this autonomy
and determining whether symptoms warranted
pharmacological intervention. People with insom-
nia generally found the non-speciﬁc nature of
insomnia and the night-to-night variability in
sleep patterns difficult for determining ‘when’ and
‘how much’ medication should be taken.
To me as required is. . . for me personally as
required is when – when I can’t sleep. If I can’t
sleep or if I think I’m not going to sleep that’s
when I should take it but it is kind of a vague term
I suppose. (P12_CL, Female, Age: 29)
People with insomnia seem to struggle with
trying to strike a ﬁne balance between symptom
control and not ‘taking too much’ to minimizing
side-eﬀects. The eﬀects of this ambiguity were
more pronounced in those with co-existing
chronic conditions who frequently drew compar-
isons between the non-speciﬁc nature of
insomnia and the more prominent features of
their other condition which they relied upon to
administer medication. For example, participant
27 described relying upon the symptoms of
‘breathlessness and wheezing’ as a cue to use
their asthma medication.
. . .it’s a bit hard to determine when is required for
the things like sleeping tablets, like what deems
necessary compared to asthma medications when
it is like ‘I can’t breathe I need it’. (P27_CM,
Female, Age: 19)
Justifying medication use
In response to insomnia, patients intuitively tried
to induce sleep ‘naturally’ through using various
passive sleep-promoting strategies (e.g. drinking
herbal tea, watching television, walking around
the house or meditating). A key factor for medica-
tion use was dependent on the extent to which
individuals perceived their insomnia symptoms to
be severe enough to warrant pharmacological
intervention. Severity thresholds were either based
around night-time routines or perceived next-day
demands. During the night, medication use was
only considered appropriate after exhausting all
possible strategies and/or spending a speciﬁc per-
iod of time sleeping and/or after a certain number
of consecutive nights of poor sleep.
When I can’t fall asleep and I know that I’ve tried
the chamomile tea and the stretches or watching
TV or reading and I think ‘now it’s required’ I
mean I’ve got 5 h to sleep, these are not gonna
help or anything, I’m just going directly for Stilnox
to get this sleep and make sure I can get good night
sleep. (P45_CM, Female, Age: 51)
Alternatively, some people with insomnia
relied on the perceived importance/demand of
their next-day schedule of activities to justify their
medication use. They reasoned that they were
willing to put up with symptoms of insomnia until
they planned an important/demanding activity
for the next day or the activity itself posed as a
form of stressor that adversely aﬀected their sleep
– both of which warrantedmedication use.
Oh just if tomorrow’s a really big experiment. I
feel pressured that I need to do well, I’ll take it.
(P10_CL, Female, Age: 29)
Coping mechanisms
Participants seem to have developed a unique
set of medication-taking behaviours to allay
their concerns around the use of pharmaco-
logical sleep aids. Part of this concern stems
from the perceived harm of using medication
as well as fear of becoming resistant to the
sleep-promoting eﬀects of medication if used
too frequently. This translated to a set of
behaviours which involved periodically substi-
tuting pharmacological sleep aids for other
medication classes (e.g. sedative analgesics)
and/or rotating between complementary and
medications as they were considered to be
safer alternatives and therefore reducing the
burden of the ‘harder’ drugs.
. . .I try and spread them around but, you know,
taking the Blackmores, the herbal sleep things or
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Swisse sleep tablets, they basically do very little, if
anything. (P35_CM, Male, Age: 64)
Well, sometimes I might take a couple of Avinols
after dinner, hoping that I might relax then. If I’d
had like 3 or 4 nights of taking a Stilnox, then I’d
probably try the Periactin if I still was not going to
sleep. (P49_CL, Female, Age: 52)
The dose of the pharmacological ‘sleeping pill’
was of great importance for people with insom-
nia and was often used to gauge the state of their
sleep complaint. Taking less than the prescribed
dose of medication was regarded as a positive
health behaviour. Dose reduction was perceived
as form of harm minimization for those who
experienced difficulty coming to terms with their
sleep medication use. People with insomnia also
interpreted taking smaller doses as a sign of
recovery and resuming some level of control
over their sleep. To attest to these beliefs, partici-
pants often modiﬁed prescribed doses of
medication of their own accord.
I take half, so I suppose that makes me feel that-,
because I’m taking half-, that’s okay. (P50_CM,
Female, Age:52)
Theme 3: Following instructions
Message from the health-care professional
Interactions with health-care professionals
(HCPs) pertaining to the use of sleep aids were
restricted to primary care doctors at the point of
prescribing and/or community pharmacists
when receiving an OTC product and/or a pre-
scription item. The description of the nature and
depth of the interaction was almost always
dependent on the history of the participants’
medication use. For those encountering a HCP
for the ﬁrst time, the counselling interaction
focused on restricting the time course of medica-
tions to ‘short-term’, potential side-eﬀects and
the addictive nature of hypnotics. Similarly, par-
ticipants who sought OTC sleep aids from
pharmacists recalled being counselled on the
adverse eﬀects of sedative antihistamines and
the potential for ﬁrst-dose response sensitivity
(i.e. residual sedation). With the exception of
one participant (P11), complementary sleep aids
rarely involved HCP input and the instructions
on the packaging was relied upon. On the other
hand, those with a long-standing use of pharma-
cological sleep aids reported receiving relatively
little counselling once their HCP conﬁrmed that
they had previously used the same medication.
This subset of participants revealed much of
what they understand about their medication
was largely informed by their own experiences.
However, neither patient group recalled being
told the beneﬁts of treatment or what to expect
from treatment as part of their overall insomnia
management plan.
. . .he would stipulate to try and not take it every
night and um and I think I only got like sort of I
think two or three scripts over you know over I
suppose um a 5 month period um yeah he was
really adamant that I didn’t take them every
night. . . (P1_CM, Female, Age 45)
. . .when he ﬁrst gave it to me- ‘yep it’s addictive
um. . . don’t take it any longer than um. . . a week
or 2 weeks um. . .but he didn’t really go through
any information at the time. Um. . .it was only
since I started taking it that I saw other people had
bad reactions but since I’ve never had anything. . .
any problems with it I don’t worry about it too
much. (P12_CL, Female, Age: 29)
Some chemists just might say ‘have you had this
before’ I said ‘oh yeah I’ve had it before’, they say
‘ok here it is’. There’s no speciﬁc warnings by-, I
assume there are warnings but they probably just
say ‘have you had it before’. . . (P35_CM, Male,
Age: 64)
Problems perceived, problems resolved
Both users and non-users of pharmacological
sleep aids agreed that ‘when required’ is an
ambiguous instruction to follow because it was
open for interpretation by the individual. Those
with a long-standing history of hypnotic use felt
they had acquired extensive knowledge about
their medication and believe that they had devel-
oped a sensible approach in their current
medication-taking routine in terms of gauging
their symptoms and determining when and how
much medication is needed. However, similar
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concerns resonated between both subsets of par-
ticipants particularly with respect to the lack of
an objective standard for determining symptom
severity. People with insomnia related the
instruction to their illness experiences and rea-
soned that everyone has a diﬀerent threshold for
tolerating symptoms, that is those with a low
tolerance can potentially overuse medication,
whereas those with a high tolerance may under-
use medication. Similarly, when ‘prn’ is applied
in the context of multiple wakenings, it can
result in repeated medication use.
So if you can’t sleep all the time and you’re taking
one every time you’re trying to get to sleep, you
could be trying to get to sleep two-three times a
day. . .maybe. (P23_CL, Female, Age: 42)
I suppose ‘when required’ it requires you to be able
to identify when you are in need of the drug’s
assistance which is a-, it’s a bit risky actually,
because it requires the person to be able to identify
the symptoms and the extent of the symptoms.
(P41_CL, Female, Age: 20)
Comments were made relating to the need for
a more speciﬁc set of instructions to address
current ambiguity. Suggestions made revolved
around improving symptom recognition and set-
ting quantiﬁable boundaries for the amount and
timing of medication use.
More information about how often to take it with
an actual number so if you can quantify that
rather than being open and vague I think is better.
(P8_CM, Female, Age: 27)
It probably would help to be more speciﬁc rather
than saying ‘as required’. . . If it is one a day and
your allowed to safely take one a day, then I
think that needs to be speciﬁc, you need to say,
‘you’re able to take one a day’. (P42_CM,
Female, Age: 46)
Precautionary measures
There was a general familiarity with the ‘Label
1‡ ’ ancillary due to its widespread application
across the medications they have previously used
(sleep and non-sleep related). The extent to
which people with insomnia paid attention to
this label appeared to be inﬂuenced by their
familiarity with the medication in question and
the presence of psychosocial responsibilities
which can potentially be aﬀected. Those who
had used a medication on an on-going basis
tended to pay little attention to the label and
became increasingly complacent over the years
because they were familiar with their body’s
response to medication.
I was pretty sure I wasn’t meant to be driving and
I did you know just built- you know I just got used
to them um. . . yeah so I’ve been arrogant, very
arrogant about that stuﬀ. (P2_CL, Female, Age:
54)
Conversely, participants without prior experi-
ences with the pharmacological sleep aids or
those who were engaged in activities involving
children (e.g. driving children to school) paid
closer much attention to the warnings and exer-
cised greater caution. Interestingly, participants
enlisted similar resources and people to delegate
tasks to.
Yeah, that’s in my mind and when I took the
Temazepam, I had to say to my husband you need
to get up to the kids if something happens ‘cause
yeah.’ (P23_CL, Female, Age: 42)
I’d rather say ‘Guys I am taking a week oﬀ, I am
on this thing I’ve got to take this prescription, so I
cannot drive any vehicle or operate any equipment
for the next week. (P37_CM, Male, Age: 48)
When asked about the interpretation of this
ancillary label, many thought the warnings and
the eﬀects of medication were restricted to the
period of their sleep with the assumption that
the medication would clear out of the system
overnight. Participants reasoned that sedation is
a desired outcome of taking a pharmacological
‘sleeping pill’ and found the warning to be some-
what counterintuitive. Nonetheless, of those
taking pharmacological sleep aids (n = 43), over
half reported experiencing residual sedation and
described the symptoms in terms of ‘grogginess’
or a ‘hangover’. However, individuals did not
‡Label 1 is an ancillary label used in Australia which states:
‘This medicine may cause drowsiness and may increase the
eﬀects of alcohol. If aﬀected, do not drive a motor vehicle or
operate machinery’.
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perceive these non-speciﬁc symptoms to be sev-
ere enough to warrant alternative arrangements,
felt they had eﬀective coping strategies or had
adequate procedures to gauge whether or not
they were aﬀected by medication.
. . .as long as I feel like I can string a sentence
together and I’m not wonky or anything then I’ll
still drive. If I’m just a little bit drowsy I’ll drive.
(P12_CL, Female, Age: 29)
Discussion and conclusion
Discussion
To our knowledge, this is the ﬁrst in-depth quali-
tative study exploring medication use from a
diverse spectrum of the help-seeking insomnia
patient population (i.e. specialist clinic and com-
munity patient population). Research in this
area has to date focused on addressing issues of
drug dependence, drug burden and implement-
ing medication-tapering programmes.11 Our
ﬁndings extend beyond this and reveal patient
beliefs and counter-productive behavioural prac-
tices (e.g. dosage modiﬁcation) which might
perpetuate medication use for insomnia.
Despite widespread hypnotic use for manag-
ing insomnia,2 both users and non-users of
pharmacological sleep aids shared negative
views towards pharmacotherapy and appears to
be an intrinsic response even across other more
‘acceptable’ conditions like asthma.33 We also
noted the shift in attitude towards complemen-
tary medicines where individuals were willing to
trade-oﬀ perceived efficacy for lower risk of
potential side-eﬀects. Prioritizing safety over effi-
cacy has also been observed in another study
exploring the use of natural sleep aids in a com-
munity pharmacy patient population where
similar prioritizing strategy adopted by patients
and may be a fundamental part of patients’ risk
management strategies.18,34 Despite the popular-
ity of complementary therapies and its high
levels of intrinsic acceptability among patients
with insomnia, the efficacy and potential
adverse consequences of such products remain
inconclusive.35 Using ineﬀective treatments not
only delays the resolution of symptoms but
potentially perpetuates the development of
chronic insomnia which becomes considerably
more difficult to treat.36
Users of pharmacological sleep aids appear to
closely adhere to HCPs’ instructions to limit med-
ication use to only ‘when required’. However,
patient interpretations are complicated by night-
to-night sleep variability, negative societal mes-
sages constructed around the pharmacological
‘sleeping pill’37 and HCPs’ counselling focus on
adverse eﬀects. This is also reﬂected in patient
BMQ-Harm scores (Table 1) which indicate a
general perception of medications doing more
harm than good. For the individual, their logic of
‘less is better’ seems consistent with these mes-
sages as many begin to scrutinize over the
accuracy of interpreting ‘required’ leading to ten-
tative medication use. Uncertainty leads
individuals to self-titrate doses of prescribed and/
or OTC sleep aids, spreading out single doses
across the night, delaying medication use or
periodically substituting the pharmacological
‘sleeping pill’ with complementary agents and
sedating analgesics (e.g. codeine). Such beha-
vioural patterns are described by Fainzang34 as
strategies of reduction and rearrangement and
may form the basis how individuals exercise
‘pharmacovigilance’ in their own social context.38
Similar compensatory health beliefs are often
reported in the tobacco cessation literature where
one ‘unhealthy’ behaviour is deemed to be neutral-
ized by another ‘volitional healthy behaviour’.39
While participants considered their current
practices to be positive health behaviours that
eﬀectively ‘neutralize’ perceived risks and medi-
cation load, they may in fact be compromising
medication eﬀectiveness. Many of the patient-
reported modiﬁcations render formulations
subtherapeutic (e.g. quartering control-release
formulations) and may merely be exerting a
placebo eﬀect which falsely reinforces such prac-
tices as ‘safer’.40 Furthermore, the sporadic use
of the various complementary remedies and
‘safer’ drugs (e.g. paracetamol) puts the patient
at greater risk of drug–drug and/or herb–drug
interactions particularly when these practices
are considered ‘safe’ and ‘sensible’ and therefore
not communicated to the clinician.18 Similar
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observations of medication down-titrating/
substitution among insomnia patients have also
been documented by Henry.41 This might be an
important set of safety behaviours through which
the patient comes to terms with their medication
use by reassuming control over sleep and gauge
their recovery.
The compulsion to justify medication need
can be explained by participants’ ‘less is better’
logic. Many rely on tangible medication-taking
cues through assessing next-day activities or
undertaking an extensive list of passive sleep-
inducing strategies to ‘wait for sleep to come’.
The latter may be counter-productive given pas-
sive strategies are ineﬀective42 and repeated
distress from exposure of unsuccessful strategies
prior to medication taking inadvertently condi-
tions the patient to associate medication with
sleep.43 This might be one possible mechanism
through which psychological dependence occurs
as the patient transitions from an acute to a
chronic hypnotic user despite many viewing the
pharmacological ‘sleeping pill’ as a short-term
solution and disliking the medication,44 much
like staying in bed longer perpetuates insom-
nia.45 Delaying medication use at night also
poses safety concerns relating to residual sedat-
ing eﬀects the following day and have been
implicated in road-traffic accidents.4,5,46 How-
ever, most participants felt ‘Label 1’ instructions
applied to the immediate hours following medi-
cation use and/or were conﬁdent about
managing this ‘grogginess’ when driving. Similar
levels of ambivalence have been observed in the
use of the ‘yellow/black’§ label in the Nether-
lands.16 Including ‘categories of impairment’
and pictograms in warning labels have been
shown to improve risk communication to the
patient and positively modulate risk behaviours
and thus warrants further research on its feasi-
bility in Australian primary care.47
Whilst this study captured diverse experiences
from a community (55%) and clinic (45%)
patient population, there are a number of limita-
tions. Our participants represent a self-selected
group who might be more actively engaged in the
management of their insomnia and thus do not
necessarily reﬂect the views of those who are less
interested in the topic. Throughout the interview,
participants were often asked to retrospectively
report their treatment history and thus issues of
recall accuracy should be considered. For a small
patient subgroup without prior exposure to sleep
aids (P8, P16 and P37), their perception towards
medication was constructed around a hypotheti-
cal scenario, but nonetheless provide important
insight that is representative of those in the early
phases of help-seeking and consulting the pre-
scriber for the ﬁrst time. Further, the vast
majority of interviews were conducted using the
telephone (n = 36) and while body language and
facial expressions cannot be assessed, the partici-
pants may have been more comfortable about
revealing their current medication experiences
given the anonymity of the situation.
Conclusion
A mismatch exists between HCPs’ provision of
instructions and labelling and how the patient
understands, interprets and applies this knowl-
edge. Current instructions and labelling do not
necessarily promote the quality use of hypnotics
and could be contributing to the costly conse-
quences of incorrect hypnotic use.9,48 Instruction
ambiguity poses further challenges for the patient
struggling to come to terms with their medication
use along with the variability of night-to-night
sleep patterns. Reﬁning labelling and education
where clinicians work with patients to identify
patient-speciﬁc cues (i.e. symptoms ‘when unable
to sleep’), set days for medication use, specify-
ing doses/dosage intervals (e.g. one tablet to be
taken at once) and timeframe (e.g. 30 min
before desired bedtime) are potential ways for
optimizing pharmacotherapy and preventing
downstream chronic hypnotic use.
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